Last viewed: ONCY


Prices are updated after-hours



nasdaq:ONCY Oncolytics Biotech Inc.

ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (2.6% 1m) (-43.0% 1y) (0.6% 2d) (-1.3% 3d) (0.0% 7d) (-100.0% volume)
http://www.oncolyticsbiotech.com
Sec Filling | Patents | 23 employees

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

add to today's watch list email alert is off




pathogens   treatment  

Press-releases


Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
Published: 2022-01-14 (Crawled : 17:00) - prnewswire.com
ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology
| | O: 0.65% H: 0.0% C: 0.0%
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology
| | O: 0.17% H: 0.0% C: 0.0%
PFE | News | $53.68 | twitter stocktwits trandingview |
Health Technology
| | O: -1.01% H: 0.0% C: 0.0%
AZNCF | News | $119.67 | twitter stocktwits trandingview |
Health Technology
| | O: -0.21% H: 0.98% C: 0.98%
INCY | $74.78 | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.0% C: 0.0%

treatment cancer breast cancer merge
Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 Outlook
Published: 2022-01-11 (Crawled : 13:30) - biospace.com/
ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology
| | O: 1.88% H: 0.0% C: 0.0%


Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer
Published: 2021-12-21 (Crawled : 13:00) - biospace.com/
ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology
| | O: 0.67% H: 3.33% C: 0.67%

biotech ema iot
Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting
Published: 2021-12-15 (Crawled : 12:30) - prnewswire.com
ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology
| | O: -0.63% H: 0.64% C: -1.27%

biotech ema ces presentation preclinical iot
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
Published: 2021-12-10 (Crawled : 19:00) - prnewswire.com
BMY | $64.72 | twitter stocktwits trandingview |
Health Technology

MRTX | $118.45 | twitter stocktwits trandingview |
Health Technology

AMGN | News | $233.74 | twitter stocktwits trandingview |
Health Technology

ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology

MRK | News | $80.98 | twitter stocktwits trandingview |
Health Technology

artificial intelligence drug cancer drug cancer
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Published: 2021-12-10 (Crawled : 14:00) - prnewswire.com
NKTR | $12.04 | twitter stocktwits trandingview |
Health Technology
| | O: -0.47% H: 0.0% C: 0.0%
ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology
| | O: -6.7% H: 0.0% C: 0.0%
IMGN | $5.84 | twitter stocktwits trandingview |
Health Technology
| | O: -4.78% H: 0.0% C: 0.0%
HOLX | News | $70.42 | twitter stocktwits trandingview |
Health Technology
| | O: -1.42% H: 0.0% C: 0.0%
BCTX | $8.03 | twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: -13.0% H: 0.0% C: 0.0%

treatment era therapy cancer negative breast cancer
Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium
Published: 2021-12-10 (Crawled : 12:30) - prnewswire.com
ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology
| | O: -6.7% H: 0.0% C: 0.0%

biotech phase 2 symposium trial positive cancer negative iot breast cancer
Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium
Published: 2021-11-19 (Crawled : 14:30) - biospace.com/
ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology
| | O: -2.29% H: 3.51% C: 1.75%

biotech phase 2 cancer iot breast cancer trial
Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results
Published: 2021-11-05 (Crawled : 12:15) - biospace.com/
ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology
| | O: 5.53% H: 0.0% C: -4.1%

financial results results biotech iot
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
Published: 2021-11-03 (Crawled : 13:00) - prnewswire.com
AZNCF | News | $119.67 | twitter stocktwits trandingview |
Health Technology
| | O: 1.95% H: 0.06% C: 0.06%
CLVS | $2.44 | twitter stocktwits trandingview |
Health Technology
| | O: -4.63% H: 8.31% C: 8.31%
MRK | News | $80.98 | twitter stocktwits trandingview |
Health Technology
| | O: 0.7% H: 0.0% C: 0.0%
ONCY | $1.55 | twitter stocktwits trandingview |
Health Technology
| | O: 1.4% H: 0.49% C: -1.84%
ARAY | $4.18 | twitter stocktwits trandingview |
Health Technology
| | O: 3.45% H: 3.34% C: 2.41%
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology
| | O: 1.52% H: 0.19% C: -0.19%

treatment cancer
See all


Last 15 days Sec forms
File Id Form Date Direction Code Amount Transacted Owned Amount


Your Today's Watch List
Sign in to create a watchlist
Today's Insiders Buying

Yesterday's Insiders Buying